Practitioner's Docket No. <u>5800-13B (35800/238853) (MPI98-089CP2M)</u>

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Glucksmann, Maria A., et al

Application No.:

09/964,008

Group No.:

1646

Filed:

September 26, 2001

Examiner:

O'HARA, EILEEN B.

For:

15625 RECEPTOR, A NOVEL G-PROTEIN COUPLED RECEPTOR

Commissioner for Patents Washington, D.C. 20231

REVOCATION OF PRIOR POWERS OF ATTORNEY AND APPOINTMENT OF NEW POWER OF ATTORNEY

Dear Sir:

MILLENNIUM PHARMACEUTICALS, INC., the Assignee of the entire right, title and interest in the above-identified application by virtue of the Assignment document filed with the United States Patent and Trademark Office on <u>March 11, 2002</u>, at Reel <u>012704</u>, Frame <u>0342</u> hereby revokes all Powers of Attorney with respect to that application heretofore granted and appoints the below listed attorneys with full power of substitution and revocation to prosecute this application and to transact all business in the Patent Office connected therewith.

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

with sufficient postage as first class mail.

as "Es

as "Express Mail Post Office to Address" Mailing Label No. <u>EV292721934US</u>

TRANSMISSION transmitted by facsimile to the Patent and Trademark Office.

Signature

Date: ___April 3, 2003

Sean Hunziker/Carolyn Willey

(type or print name of person certifying)

^{*}WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Practitioner's Docket No. 5800-13B (35800/238853) (MPI98-089CP2M)

Scott A. Brown, Reg. No. 32,724; Ian R. Silverman, Reg. No. 37,443; Jean M. Silveri, Reg. No. 39,030; Allan N. Kutzenco, Reg. No. 38,945, Janice M. Klunder, Reg. No. 41,121; Theodore R. Allen, Reg. No. 41,578; Kerri Pollard Schray, Reg. No. 47,066, Tracy M. Sioussat, Reg. No. 50,609; and Paul J. Paglierani, Reg. No. 52,498

all of Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, Massachusetts 02139, United States of America.

Please direct all future correspondence to:

Intellectual Property Group
MILLENNIUM PHARMACEUTICALS, INC.
75 Sidney Street
Cambridge, MA 02139

and direct all telephone calls to <u>Jean M. Silveri</u> at 617-679-7336

MILLENNIUM PHARMACEUTICALS, INC.

By: _____

Typed Name. Jean M. Silveri

Title: Associate General Counsel

Dated: April 3, 2003

Practitioner's Docket No. <u>5800-13B</u> (<u>35800/238853</u>) <u>MPI98-089CP2M</u>

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

	n	2	ann	100	Inn	\sim	
		16	app				
-	••	•	"PP			-	•

Glucksmann, Maria A., et al

Application No.:

09/964,008

Group No.:

1646

Filed:

September 26, 2001

Examiner:

O'HARA, EILEEN B.

For:

15625 RECEPTOR, A NOVEL G-PROTEIN COUPLED RECEPTOR

Commissioner for Patents Washington, D.C. 20231

CHANGE OF ATTORNEY DOCKET NUMBER

Dear Sir:

Please note that the Attorney Docket Number has been changed from

<u>5800-13B (35800/238853)</u> to <u>MPI98-089CP2M</u>. Please reference <u>MPI98-089CP2M</u> on all future correspondence.

Respectfully submitted,

April 3, 2003

MILLENNIUM PHARMACEUTICALS, INC.

By Jean M. Silvei

Attorney/Agent for Applicant Registration No. 39,030

75 Sidney Street

Cambridge, MA 02139 Telephone - 617-679-7336 Facsimile - 617-551-8820

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

with sufficient postage as first class mail.

April 3, 2003

Œ

as "Express Mail Post Office to Address"
Mailing Label No. <u>EV292721934US</u>

TRANSMISSION

Transmitted by facsimile to the Patent and Trademark Office.

Signature

The state of the s

Sean Hunziker/Carolyn Willey
(type or print name of person certifying)

(type or print name of person certifying)

*WARNING:Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

(Page 1 of 1)